[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abnormal-uterine-bleeding-aub\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abnormal-uterine-bleeding-aub":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,98,121,156,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100634822","endometrial-cancer-vaginal-fluid-specimen-collection-study-100634822",false,"NCT07544680","Endometrial Cancer Vaginal Fluid Specimen Collection Study","Endometrial Cancer Vaginal Fluid Specimen Collection Study: \"ENVISION\"","ENVISION","Inclusion Criteria\n\nCohort 1 Participants:\n\n* Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor\n* Diagnosed with abnormal uterine bleeding (AUB)\n* Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia (AEH\u002FEIN)\n\nCohort 2 Participants:\n\n* Age ≥ 18 years\n* Newly diagnosed, biopsy-confirmed EC or AEH\u002FEIN\n* Planning initial management for their endometrial pathology\n\nExclusion Criteria\n\n* Prior partial or complete hysterectomy\n* Current pregnancy\n* Prior pelvic or vaginal radiotherapy\n* Chemotherapy within past 5 years (except tamoxifen)\n* Any condition judged by the Investigator to preclude participation\n\nAdditional for Cohort 1:\n\n* Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)\n* Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia\n* Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp\n* Benign endometrial biopsy within last month\n\nAdditional for Cohort 2:\n\n* Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)\n* Prior cervical cancer or biopsy-proven cervical dysplasia\n* Surgery for recurrent EC\n* Preoperative neoadjuvant chemotherapy or radiotherapy for current EC\n* Prior treatment or surgery to remove target pathology during current episode","FEMALE","18 Years",{"count":20,"type":21},4200,"ESTIMATED","OBSERVATIONAL","This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.",[25,26,27,28,29],"Abnormal Uterine Bleeding (AUB)","Endometrial Cancer","Atypical Endometrial Hyperplasia","Endometrial Hyperplasia With Atypia","Endometrial Intraepithelial Neoplasia",[25,31,32,33,34,35,36,37,38,39],"Endometrial Cancer (EC)","Atypical Endometrial Hyperplasia (AEH)","Endometrial Hyperplasia with Atypia","Endometrial Intraepithelial Neoplasia (EIN)","Precancerous Conditions","Post-Menopausal Bleeding","Specimen Collection","Sample Collection","in vitro diagnostic (IVD) devices","RECRUITING","2026-08-19",{"date":43,"type":44},"2026-08-20","ACTUAL",{"date":46,"type":44},"2026-03-10",{"date":48,"type":21},"2028-04-24",{"name":50,"class":51},"Exact Sciences Corporation","INDUSTRY",5,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100649200","deep-neuromuscular-blockade-and-a-low-residue-diet-for-the-surgical-field-in-vnotes-hysterectomy-100649200","NCT07730970","Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES Hysterectomy","Effect of Deep Neuromuscular Blockade and a Preoperative Low-Residue Diet on Intra-operative Surgical Field Conditions During Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Hysterectomy: A 2×2 Factorial, Assessor-Blinded Randomized Controlled Trial","vNOTES_NMBDIET","Inclusion Criteria:\n\n* Adult women (aged 18 years or older) scheduled for hysterectomy for a benign (non-cancer) indication.\n* Judged suitable for the vNOTES approach by the operating surgeon.\n* Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Suspected or known gynaecological malignancy.\n* Conditions expected to make the approach or the field assessment non-standard (e.g., anticipated dense pelvic adhesions or severe endometriosis, a contraindication to vNOTES, or an obliterated cul-de-sac).\n* Any medical reason why deep neuromuscular blockade or sugammadex would be unsafe (defined with the anaesthesia team).\n* Any medical reason why a low-residue diet would be unsuitable.\n* Inability to give informed consent.",{"count":62,"type":21},160,"INTERVENTIONAL",[65],"NA","vNOTES (vaginal natural orifice transluminal endoscopic surgery) hysterectomy is performed entirely through the vagina, with no abdominal incision. A clear surgical view is essential, and the main obstacle to the view is bowel falling into the pelvis. This randomized trial tests whether two simple measures improve the surgical field, individually or in combination: a preoperative low-residue diet for three days, and deeper intra-operative muscle relaxation (deep neuromuscular blockade). No group receives mechanical bowel preparation.\n\nUsing a 2×2 factorial design, participants are allocated equally (1:1:1:1) to one of four groups: (1) no diet with standard relaxation; (2) diet with standard relaxation; (3) no diet with deep relaxation; (4) diet with deep relaxation (the \"bundle\"). The surgical field is measured objectively: during a standardized window the carbon-dioxide insufflation pressure is lowered step by step, and 2-3 blinded assessors score the field from de-identified video. The primary outcome is the lowest pressure at which the field remains adequate; a lower pressure indicates an intrinsically better field.\n\nThe trial hypothesis is an interaction - that the combination achieves an adequate field at a meaningfully lower pressure than either measure alone. The final sample size is determined from an internal pilot. Secondary outcomes include the continuous field score, the need for an additional instrument to clear the field, postoperative nausea and vomiting, and routine operative outcomes.",[68,69,25,70,71],"Leiomyoma, Uterine","Benign Gynecological Disease","Uterine Prolapse","Adenomyosis of Uterus",[73,74,75,76,77,78,79,80,81,82,83,84,85,86],"vNOTES","vaginal natural orifice transluminal endoscopic surgery","deep neuromuscular blockade","rocuronium","post-tetanic count","low-residue diet","bowel preparation","insufflation pressure","pneumoperitoneum","surgical field","visualization","objective visualisation index (OVI)","factorial trial","assessor-blinded","2026-07-29",{"date":89,"type":44},"2026-07-30",{"date":91,"type":44},"2026-07-01",{"date":93,"type":21},"2027-09-01",{"name":95,"class":96},"Fatih Sultan Mehmet Training and Research Hospital","OTHER",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":63,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100649190","pipelle-versus-manual-vacuum-aspiration-cannula-for-endometrial-biopsy-in-women-with-abnormal-uterine-bleeding-100649190","NCT07731581","Pipelle Versus Manual Vacuum Aspiration Cannula for Endometrial Biopsy in Women With Abnormal Uterine Bleeding","A Comparative Study of Pipelle Versus Manual Vacuum Aspiration Cannula for Endometrial Biopsy","Inclusion Criteria:\n\n1. Married women aged 35 years and above.\n2. Presentation with abnormal uterine bleeding (AUB), including but not limited to metrorrhagia, menorrhagia, or postmenopausal bleeding.\n3. Clinical indication for endometrial sampling for diagnostic evaluation of abnormal uterine bleeding.\n4. Patient fit for both MVA and Pipelle procedures, with no contraindications to either method.\n\nExclusion Criteria:\n\n1. Pregnancy or suspicion of pregnancy.\n2. Acute pelvic inflammatory disease or active genital tract infection.\n3. Current use of anticoagulant therapy or presence of bleeding disorders that pose a risk for excessive bleeding during endometrial sampling.","35 Years",{"count":107,"type":21},80,[65],"women globally, often requiring endometrial tissue sampling for accurate evaluation and diagnosis. Traditional office-based sampling techniques like Pipelle are widely used, but the disposable instruments can be relatively expensive in resource-limited settings. Manual Vacuum Aspiration (MVA) using a flexible cannula is an inexpensive, reusable alternative, but clinical data comparing its performance directly to Pipelle remains limited.\n\nThe objective of this randomized clinical trial is to compare Pipelle endometrial biopsy and Manual Vacuum Aspiration (MVA) cannula in terms of sample adequacy, patient satisfaction, and post-procedure complications in women presenting with abnormal uterine bleeding. Participants will be randomly assigned to undergo endometrial sampling using either a 4 mm MVA cannula or a Pipelle device without anesthesia or cervical dilation. Samples will be analyzed for histopathological diagnosis, and outcomes such as procedure pain, adequacy of tissue, and complications will be recorded.",[25],"NOT_YET_RECRUITING","2026-07-22",{"date":114,"type":44},"2026-07-28",{"date":116,"type":21},"2026-08-11",{"date":118,"type":21},"2027-08-12",{"name":120,"class":96},"University of Health Sciences Lahore",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":63,"phases":130,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":155},"100646011","office-hysteroscopy-in-postmenopausal-women-a-randomized-trial-of-cervical-preparation-strategies-100646011","NCT07697781","Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies","A Four-Arm Prospective Randomized Controlled Trial Comparing Oral Misoprostol, Two Vaginal Estrogen Regimens, and No Cervical Preparation Before Office Hysteroscopy in Postmenopausal Women","Inclusion Criteria:\n\n* Women with postmenopausal status.\n* Scheduled for office hysteroscopy for the evaluation of suspected intrauterine pathology.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected hormone-dependent malignancy (e.g., breast or endometrial cancer).\n* Active genital tract infection.\n* Contraindication or known hypersensitivity to misoprostol or vaginal estrogen.\n* Refusal to undergo office hysteroscopy without anesthesia.\n* Active uterine bleeding preventing adequate hysteroscopic visualization on the day of the procedure.",{"count":129,"type":21},120,[65],"The goal of this randomized controlled trial is to evaluate the effectiveness of different cervical preparation strategies before office hysteroscopy in postmenopausal women undergoing evaluation for intrauterine pathology.\n\nThe main questions to answer are:\n\nDoes cervical preparation improve the success rate of complete office hysteroscopy in postmenopausal women? Which cervical preparation strategy provides better patient tolerance, as assessed by pain intensity during the procedure?\n\nResearchers will compare four cervical preparation protocols (14-day vaginal estrogen, 7-day vaginal estrogen, oral misoprostol, and no cervical preparation) to determine their effects on procedural success, pain, procedure duration, and perioperative complications.\n\nParticipants will be randomly assigned to one of the four cervical preparation protocols. They will undergo office hysteroscopy using a vaginoscopic (\"no touch\") approach without anesthesia. Then, they will have pain assessed using a visual analog scale (VAS) during the procedure. Finally, these informations will be collected: procedural success, procedure duration, bleeding, and perioperative complications.",[133,134,135,136,25],"Postmenopausal Women","Intrauterine Diseases","Endometrial Pathology","Postmenopausal Bleeding",[138,139,140,141,142,143,144,145,146],"Postmenopausal women","Postmenopausal bleeding","Office hysteroscopy","Cervical preparation","Vaginal estrogen","Oral misoprostol","Visual Analog Scale","Vaginoscopy","No touch approach","2026-07-09",{"date":149,"type":44},"2026-07-13",{"date":151,"type":44},"2026-01-02",{"date":43,"type":21},{"name":154,"class":96},"Faculty of Medicine of Tunis",1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":164,"enrollmentInfo":165,"targetDuration":167,"studyType":22,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":155},"100645844","menstrual-cycle-symptoms-and-female-health-100645844","NCT07699224","Menstrual Cycle Symptoms and Female Health","Prevalence of Subclinical Ovulatory Disturbances and Symptoms During the Menstrual Cycle and Their Relationship With Physical and Mental Health in Spanish Women of Reproductive Age (Prevalencia de Alteraciones Ovulatorias subclínicas y síntomas Durante el CICLO Menstrual y su relación Con la Salud física y Mental en Mujeres españolas en Edad Reproductiva).","CICLOS","Inclusion Criteria:\n\n* Females\n* Between 18 and 45 years\n* Naturally menstruating.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Hormonal contraceptive methods during the 6 months before the study.\n* hysterectomy or ooforectomy.\n* Smoking.","45 Years",{"count":166,"type":21},400,"5 Months","The complexity inherent to the hormonal fluctuations associated with the female menstrual cycle (MC) has contributed, from a methodological perspective in research, to the neglect of women's physiological characteristics and to the silencing and normalization of symptoms linked to different life stages and hormonal environments. The scarce and outdated available data suggest high percentages of women experiencing perimenstrual symptoms, such as premenstrual syndrome or menstrual pain, as well as intermenstrual discomfort. These symptoms not only significantly impair daily activities but, due to their normalization, often lead to the underdiagnosis of other gynecological conditions.\n\nSubclinical ovulatory disturbances-characterized by the suppression of ovarian hormones as an adaptive defense mechanism against various environmental stressors-are also frequently underdiagnosed. These disturbances typically do not affect MC length, making them difficult to detect, and although the process is reversible, it may initiate irreversible consequences for certain tissues, such as bone mass loss. However, neither women nor their educational, occupational, or healthcare environments appear to have the resources and\u002For knowledge required to adequately address these issues.\n\nAll of this may compromise women's rights to adequate sexual and reproductive health and to a dignified quality of life, as recognized under the second line of Axis 4, \"Effective Rights for All Women,\" of the Strategic Plan for Effective Equality between Women and Men 2022-2025. Therefore, the aims of this multicenter project-carried out by a multidisciplinary research team from seven Spanish universities and three international institutions-are to describe the prevalence of symptoms and alterations related to the MC in women of reproductive age and to identify their associations with physical and mental health.\n\nTo accomplish this, an observational study will be conducted in a large sample of women of reproductive age, including multiple symptom and perceived-health questionnaires and ovulation monitoring. In addition, in a subsample of participants, bone mineral density will be assessed, blood levels of sex hormones will be monitored, and an innovative analysis of health biomarkers (glycemic and lipid profile, and inflammation) from menstrual blood will be included. This will be complemented by a qualitative study of experiences related to MC-associated symptoms and alterations, using in-depth interviews and thematic content analysis.\n\nThe findings of this project are expected to support various dissemination and educational actions, justify the design of more inclusive educational and healthcare policies, and enhance the understanding of women's needs, ultimately contributing to improved symptom management and quality of life.",[170,171,172,25,173,174],"Menstrual Cycle","Menstrual Distress (Dysmenorrhea)","Premenstrual Syndrome","Ovulation Disorder","Perceived Health Status","2026-07-08",{"date":149,"type":44},{"date":178,"type":44},"2026-01-21",{"date":180,"type":21},"2026-12",{"name":182,"class":96},"Universidad Rey Juan Carlos",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":155},"100645671","clinical-efficacy-and-safety-of-dydrogesterone-in-the-treatment-of-abnormal-uterine-bleeding-during-puberty-100645671","NCT07703488","Clinical Efficacy And Safety of Dydrogesterone In The Treatment Of Abnormal Uterine Bleeding During Puberty","Clinical Efficacy and Quality of Life Assessment of Dydrogesterone in Managing Abnormal Uterine Bleeding of Ovulatory Disorders in Adolescents：A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n* Female patient between 10-19 years old, already experiencing menarche and at least 6 months away from menarche\n* According with the criteria of Abnormal Uterine Bleeding of Ovulatory Disorders: irregular menstrual cycles (cycle interval\\\u003C21 days or\\>45 days, or adjacent menstrual intervals\\>90 days), prolonged menstrual periods (\\>7 days), excessive menstrual flow, poor bleeding control (score\\>100 on the menstrual bleeding assessment scale, or a significant increase in the frequency of changing hygiene products) within the past 3 months, and has ruled out pregnancy related and obvious structural causes.\n* The guardian of the subject signs the informed consent and obtains the consent of the subject.\n* With complete baseline clinical data: complete blood count, serum ferritin, Six types of sex hormones(FSH, LH, E2, P, T, PRL), Gynecological Sonography.\n\nExclusion Criteria:\n\n* Coagulation disorder\n* Requiring long-term anticoagulant and antiplatelet therapy\n* Secondary Abnormal Uterine Bleeding caused by uncontrolled hyperthyroidism, hypothyroidism, hyperprolactinemia, or other endocrine diseases.\n* Dysfunction of kidney and liver, or a history of severe intolerance or allergy to dydrogesterone, medroxyprogesterone, or other progestogens.","10 Years","19 Years",{"count":193,"type":21},240,"This multicenter prospective cohort study evaluates the clinical efficacy and safety of dydrogesterone versus drospirenone and ethinylestradiol in adolescents aged 10-19 years with abnormal uterine bleeding-ovulatory dysfunction (AUB-O). Patients who meet the FIGO PALM-COEIN criteria for AUB-O, have complete baseline clinical data, and provide guardian consent with adolescent assent are enrolled. Participants are allocated to receive either dydrogesterone or drospirenone and ethinylestradiol according to routine clinical practice. The primary outcome is the 6-month menstrual normalization rate (cycle length 21-35 days). Secondary outcomes include breakthrough bleeding, recurrence, adverse events, and quality-of-life improvements. Follow-up is conducted during treatment and for 6 months after treatment cessation, during which menstrual normalization is evaluated based on changes in menstrual cycle patterns and examination findings. The findings may help clarify the comparative effectiveness and safety of these two hormonal regimens for long-term cycle management in adolescents with AUB-O.",[25,196],"Ovulation Dysfunction",[198,199,200,201,202,203],"Abnormal Uterine Bleeding","Ovulation dysfunction type","Dydrogesterone","Drospirenone And Ethinylestradioare","Adolescence","Prospective Cohort",{"date":205,"type":44},"2026-07-14",{"date":207,"type":44},"2026-07-06",{"date":209,"type":21},"2028-07-28",{"name":211,"class":96},"Guangdong Women and Children Hospital"]